Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences

Enanta Pharmaceuticals, Inc. ENTA, a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the following investor conferences:

September 6, 9:40 am ET; Baird 2018 Global Healthcare Conference, New York

September 13, 8:00 am ET; Morgan Stanley 16^th Annual Global Healthcare Conference, New York

A live webcast of each presentation will be accessible by visiting the "Events and Presentations" section on the "Investors" page of Enanta's website at www.enanta.com. A replay of the webcasts will be available following the presentation and will be archived for approximately 30 days.

About Enanta

Enanta Pharmaceuticals is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Two protease inhibitors, glecaprevir and paritaprevir, discovered and developed through Enanta's collaboration with AbbVie, have now been approved around the world as part of AbbVie's regimens for the treatment of hepatitis C virus (HCV) infection, sold under the tradenames MAVYRET™ (U.S.) and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir) and VIEKIRAX® (paritaprevir/ritonavir/ombitasvir) (ex-U.S.).

Royalties from the AbbVie collaboration are helping to fund Enanta's research and development efforts, which are currently focused on the following disease targets: non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). Please visit www.enanta.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180827005328/en/